Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis

Michihide Tokuhira, Reiko Watanabe, Tomoe Nemoto, Morihiko Sagawa, Tatsuki Tomikawa, Jun Ichi Tamaru, Shinji Itoyama, Hayato Nagasawa, Koichi Amano, Hideto Kameda, Tsutomu Takeuchi, Shigehisa Mori, Masahiro Kizaki

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Despite numerous attempts to uncover the mechanism of other iatrogenic immunodeficiency-associated lymphoproliferative diseases (OIIA-LPDs), this mechanism remains poorly understood, especially in rheumatoid arthritis (RA) patients. We analyzed the data on 23 patients with LPDs and RA. Patients were categorized into three groups according to whether they had methotrexate (MTX); MTX-regressive LPDs, MTX-persistent LPDs or other drugs-mediated LPDs. The LPDs seen in OIIA-LPDs-RA might have a unique behavior to think about several rare phenotypes. The overall survival of all patients was 74% at 5 years, and those of the three groups were 100%, 64% and 60%, respectively. Among the 6 patients who died, 4 had LPDs that were detected late, and thus adequate treatment was not given. In addition, several patients with diffuse large B cell lymphoma with a complex karyotype achieved complete remission (CR). Only one among the 17 patients who achieved CR relapsed. OIIA-LPDs-RA appeared to have a better prognosis than other more common types of lymphomas. Regarding RA treatment, various anti-RA drugs were given to the patients after developing LPDs, including MTX, but no recurrent patients were documented.

Original languageEnglish
Pages (from-to)616-623
Number of pages8
JournalLeukemia and Lymphoma
Volume53
Issue number4
DOIs
Publication statusPublished - 2012 Apr

Fingerprint

Rheumatoid Arthritis
Methotrexate
Lymphoma, Large B-Cell, Diffuse
Karyotype
Pharmaceutical Preparations
Lymphoma
Phenotype
Survival
Therapeutics

Keywords

  • Iatrogenic
  • Lymphoproliferative disorder
  • Methotrexate
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. / Tokuhira, Michihide; Watanabe, Reiko; Nemoto, Tomoe; Sagawa, Morihiko; Tomikawa, Tatsuki; Tamaru, Jun Ichi; Itoyama, Shinji; Nagasawa, Hayato; Amano, Koichi; Kameda, Hideto; Takeuchi, Tsutomu; Mori, Shigehisa; Kizaki, Masahiro.

In: Leukemia and Lymphoma, Vol. 53, No. 4, 04.2012, p. 616-623.

Research output: Contribution to journalArticle

Tokuhira, M, Watanabe, R, Nemoto, T, Sagawa, M, Tomikawa, T, Tamaru, JI, Itoyama, S, Nagasawa, H, Amano, K, Kameda, H, Takeuchi, T, Mori, S & Kizaki, M 2012, 'Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis', Leukemia and Lymphoma, vol. 53, no. 4, pp. 616-623. https://doi.org/10.3109/10428194.2011.625101
Tokuhira, Michihide ; Watanabe, Reiko ; Nemoto, Tomoe ; Sagawa, Morihiko ; Tomikawa, Tatsuki ; Tamaru, Jun Ichi ; Itoyama, Shinji ; Nagasawa, Hayato ; Amano, Koichi ; Kameda, Hideto ; Takeuchi, Tsutomu ; Mori, Shigehisa ; Kizaki, Masahiro. / Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. In: Leukemia and Lymphoma. 2012 ; Vol. 53, No. 4. pp. 616-623.
@article{55e518fa1bd34d64828090153fb70e42,
title = "Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis",
abstract = "Despite numerous attempts to uncover the mechanism of other iatrogenic immunodeficiency-associated lymphoproliferative diseases (OIIA-LPDs), this mechanism remains poorly understood, especially in rheumatoid arthritis (RA) patients. We analyzed the data on 23 patients with LPDs and RA. Patients were categorized into three groups according to whether they had methotrexate (MTX); MTX-regressive LPDs, MTX-persistent LPDs or other drugs-mediated LPDs. The LPDs seen in OIIA-LPDs-RA might have a unique behavior to think about several rare phenotypes. The overall survival of all patients was 74{\%} at 5 years, and those of the three groups were 100{\%}, 64{\%} and 60{\%}, respectively. Among the 6 patients who died, 4 had LPDs that were detected late, and thus adequate treatment was not given. In addition, several patients with diffuse large B cell lymphoma with a complex karyotype achieved complete remission (CR). Only one among the 17 patients who achieved CR relapsed. OIIA-LPDs-RA appeared to have a better prognosis than other more common types of lymphomas. Regarding RA treatment, various anti-RA drugs were given to the patients after developing LPDs, including MTX, but no recurrent patients were documented.",
keywords = "Iatrogenic, Lymphoproliferative disorder, Methotrexate, Rheumatoid arthritis",
author = "Michihide Tokuhira and Reiko Watanabe and Tomoe Nemoto and Morihiko Sagawa and Tatsuki Tomikawa and Tamaru, {Jun Ichi} and Shinji Itoyama and Hayato Nagasawa and Koichi Amano and Hideto Kameda and Tsutomu Takeuchi and Shigehisa Mori and Masahiro Kizaki",
year = "2012",
month = "4",
doi = "10.3109/10428194.2011.625101",
language = "English",
volume = "53",
pages = "616--623",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis

AU - Tokuhira, Michihide

AU - Watanabe, Reiko

AU - Nemoto, Tomoe

AU - Sagawa, Morihiko

AU - Tomikawa, Tatsuki

AU - Tamaru, Jun Ichi

AU - Itoyama, Shinji

AU - Nagasawa, Hayato

AU - Amano, Koichi

AU - Kameda, Hideto

AU - Takeuchi, Tsutomu

AU - Mori, Shigehisa

AU - Kizaki, Masahiro

PY - 2012/4

Y1 - 2012/4

N2 - Despite numerous attempts to uncover the mechanism of other iatrogenic immunodeficiency-associated lymphoproliferative diseases (OIIA-LPDs), this mechanism remains poorly understood, especially in rheumatoid arthritis (RA) patients. We analyzed the data on 23 patients with LPDs and RA. Patients were categorized into three groups according to whether they had methotrexate (MTX); MTX-regressive LPDs, MTX-persistent LPDs or other drugs-mediated LPDs. The LPDs seen in OIIA-LPDs-RA might have a unique behavior to think about several rare phenotypes. The overall survival of all patients was 74% at 5 years, and those of the three groups were 100%, 64% and 60%, respectively. Among the 6 patients who died, 4 had LPDs that were detected late, and thus adequate treatment was not given. In addition, several patients with diffuse large B cell lymphoma with a complex karyotype achieved complete remission (CR). Only one among the 17 patients who achieved CR relapsed. OIIA-LPDs-RA appeared to have a better prognosis than other more common types of lymphomas. Regarding RA treatment, various anti-RA drugs were given to the patients after developing LPDs, including MTX, but no recurrent patients were documented.

AB - Despite numerous attempts to uncover the mechanism of other iatrogenic immunodeficiency-associated lymphoproliferative diseases (OIIA-LPDs), this mechanism remains poorly understood, especially in rheumatoid arthritis (RA) patients. We analyzed the data on 23 patients with LPDs and RA. Patients were categorized into three groups according to whether they had methotrexate (MTX); MTX-regressive LPDs, MTX-persistent LPDs or other drugs-mediated LPDs. The LPDs seen in OIIA-LPDs-RA might have a unique behavior to think about several rare phenotypes. The overall survival of all patients was 74% at 5 years, and those of the three groups were 100%, 64% and 60%, respectively. Among the 6 patients who died, 4 had LPDs that were detected late, and thus adequate treatment was not given. In addition, several patients with diffuse large B cell lymphoma with a complex karyotype achieved complete remission (CR). Only one among the 17 patients who achieved CR relapsed. OIIA-LPDs-RA appeared to have a better prognosis than other more common types of lymphomas. Regarding RA treatment, various anti-RA drugs were given to the patients after developing LPDs, including MTX, but no recurrent patients were documented.

KW - Iatrogenic

KW - Lymphoproliferative disorder

KW - Methotrexate

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=84859069205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859069205&partnerID=8YFLogxK

U2 - 10.3109/10428194.2011.625101

DO - 10.3109/10428194.2011.625101

M3 - Article

C2 - 21933041

AN - SCOPUS:84859069205

VL - 53

SP - 616

EP - 623

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -